Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts

Liver Transplantation

Volumn 21, Issue 1, 2015, Pages 89-95

  Considine, Aisling ^a   Tredger, J Michael ^a   Heneghan, Michael ^a   Agarwal, Kosh ^a   Samyn, Marianne ^a   Heaton, Nigel D ^a   O'Grady, John G ^a   Aluvihare, Varuna R ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISOLONE; TACROLIMUS; BIOLOGICAL MARKERS; DELAYED-ACTION PREPARATIONS; IMMUNOSUPPRESSIVE AGENTS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG RELEASE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG EFFECTS; DRUG MONITORING; DRUG SUBSTITUTION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOLOGY; KIDNEY; KIDNEY DISEASES; LONDON; MEDICATION ADHERENCE; MIDDLE AGED; PHYSIOPATHOLOGY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CREATININE; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LIVER TRANSPLANTATION; LONDON; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919665362     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24022     Document Type: Article

References (32)

1. Lamba S, Nagurka R, Desai KK, Chun SJ, Holland B, Koneru B. Self-reported non-adherence to immunesuppressant therapy in liver transplant recipients: demographic, interpersonal, and intrapersonal factors. Clin Transplant 2012;26:328-335.
2. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 2005;9:381-390.
3. European Medicines Agency. Advagraf. http://www.ema. europa.eu/ema/index.jsp?curl5pages/medicines/human/ medicines/000712/human-med-000629.jsp&mid5WC0 b01ac058001d124. Accessed September 2014.
4. Verbeeck RK, Musuamba FT. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci 2012;15:376-388.
5. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE. Once- versus twice-daily tacrolimus. Are the formulations truly equivalent? Drugs 2011;71:1561-1577.
6. Baccarani U, D'Ambrosi L, Rossetto A, Adani GL, Comuzzi C, Biletto D, et al. Once daily prolonged release (Advagraf) versus twice daily tacrolimus (Prograf) as primary immunosuppression in liver transplantation. Liver Transpl 2011;17:ss85-ss86.
7. Fischer L, Trunec? ka P, Gridelli B, Roy A, Vitale A, Valdivieso A, et al. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl 2011;17:167-177.
8. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced CO concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010;90:523-529.
9. Hougardy JM, Broeders N, Kianda M, Massart A, Madhoun P, Le Moine A, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011;91:566-569.
10. Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F, et al. Pharmacokinetics for onceversus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009;9:2505-2513.
11. Gallego-Valcarce E, Ortega-Cerrato A, Llamas-Fuentes F, Martinez-Fernandez G, Perez-Martinez J, Gomez-Roldan C. Conversion to tacrolimus extended-release formulation: short-term clinical results. Transplant Proc 2009; 41:2326-2327.
12. Lauzurica R, Morales JM, Van Hooff J; for Study Investigators. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus. Transpl Int 2012;25:48-55.
13. Kamath PS, Kim WR; for Advanced Liver Disease Study Group. The Model for End-Stage Liver Disease (MELD). Hepatology 2007;45:797-805.
14. European Medicines Agency. Guideline on bioanalytical method validation. http://www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/2011/08/ WC500109686.pdf. Accessed September 2014.
15. Fischer L, Trunec. ka P, Gridelli B, Roy A, Vitale A, Valdivieso A, et al. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl 2011;17:167-177.
16. Truneč ka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, et al; for Tacrolimus Prolonged Release Liver Study Group. Once-daily prolonged-release tacrolimus (Advagraf) versus twice-daily tacrolimus (Prograf) in liver transplantation. Am J Transplant 2010;10:2313-2323.
17. Silva HT Jr, Yang HC, Abouljoud M, Kup PC, Wisemandle K, Bhattacharya P, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/ MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007;7:595-608.
18. van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16:721-725.
19. Glowacki F, Lionet A, Hammelin JP, Labalette M, Provt F, Hazzan M, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011;50:451-459.
20. nd ed. 1997:16.
21. Ji E, Choi L, Suh KS, Cho JY, Han N, Oh JM. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation 2012;94: 866-872.
22. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
23. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-779.
24. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74:1486-1489.
25. Wehland M, Bauer S, Brakemeier S, Burgwinkel P, Glander P, Kreutz R, et al. Differential impact of the CYP3A5∗1 and CYP3A5∗3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011;21:179-184.
26. Budde K, Matz M. Tacrolimus only for breakfast . . . Transpl Int 2012;25:274-275.
27. Morrissey PE, Flynn ML, Lin S. Medication noncompliance and its implications in transplant recipients. Drugs 2007;67:1463-1481.
28. Kuypers DR, Peeters PC, Seenesael JJ, Kianda MN, Vrijens B, Kristanto P, et al; for ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation 2013;95:333-340.
29. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349: 931-940.
30. Kurnatowska I, Krawczyk J, Oleksik T, Nowicki M. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. Transplant Proc 2011;43:2954-2956.
31. Tsuchiya T, Ishida K, Ito S, Deguchi T. Effect of conversion from twice-daily to once-daily tacrolimus on glucose intolerance in stable kidney transplant recipients. Transplant Proc 2012;44:118-120.
32. Meçule A, Tinti F, Bachetoni A, Poli L, D'Alessandro M, Alessandri C, et al. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once- daily regimen. Transplant Proc 2011;43:1017-1019.